tnt .donal Application No PCT/EP 98/03318

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/85 C12N15/12 C12N15/19 C07K14/47 C07K14/52
C12N15/58 C12N9/72 C12N15/53 C12N9/02 C12N15/23
C07K14/57 C12N15/16 C07K14/58 C12N5/10 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols) IPC 6 C12N C07K A61K C12Q A01K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 17359 A (REGENTS OF UNIVERSITY OF CALIFORNIA (US); WILLIAMS L.; MORISHITA K.) 15 May 1997	1,4,10, 12,14, 16-18, 20-22, 25,40
	see abstract see page 2, line 32 - page 3, line 7 see page 45, line 4-31 see page 53 - page 59; claims	
	-/	

Further documents are listed in the continuation of box C.	X Patent family members are listed in annex.
"A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publicationdate of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filing date but	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
later than the priority date claimed	"&" document member of the same patent family
Date of the actual completion of theinternational search 23 October 1998	Date of mailing of the international search report 11/11/1998
Name and mailing address of the ISA	Authorized officer
European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijawijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni, Fax: (+31-70) 340-3016	Macchia, G

int tional Application No

A. CLASSIFICATION OF SUBJECT MATTER IPC 6 C1201/68 A01K A01K67/027 G01N33/50 A61K35/00 According to International Patent Classification (IPC) or to both national classification and IPC B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practical, search terms used) C. DOCUMENTS CONSIDERED TO BE RELEVANT Relevant to claim No. Citation of document, with indication, where appropriate, of the relevant passages RÖNICKE V ET AL: "Characterization of the 1,2 Α endothelium-specific murine vascular endothelial growht factor receptor-2 (F1k-1) promoter" CIRCULATION RESEARCH, vol. 79, no. 2, August 1996, pages 277-285, XP000604137 cited in the application see page 279, right-hand column, line 6-7 see page 280; figure 2 see page 282; figure 5B see page 283, left-hand column, line 3-9 -/--Further documents are listed in the continuation of box C. Patent family members are listed in annex. X Special categories of cited documents : "T" later document published after the international filing date or priority date and not in conflict with the application but "A" document defining the general state of the art which is not cited to understand the principle or theory underlying the considered to be of particular relevance invention "E" earlier document but published on or after the international "X" document of particular relevance; the claimed invention filing date cannot be considered novel or cannot be considered to document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention citation or other special reason (as specified) cannot be considered to involve an inventive step when the document is combined with one or more other such docu-"O" document referring to an oral disclosure, use, exhibition or ments, such combination being obvious to a person skilled document published prior to the international filing date but "&" document member of the same patent family later than the priority date claimed Date of the actual completion of theinternational search Date of mailing of the International search report 23 October 1998 Authorized officer Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentiaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016 Macchia, G

Im ational Application No PCT/EP 98/03318

		PCT/EP 98/03318
	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	Relevant to claim No.
ategory *	Citation of document, with indication, where appropriate, of the relevant passages	notovak to data 140.
A	SCHLAEGER T.M. ET AL.: "Uniform vascular-endothelial-cell -specific gene expression in both embryonic and adult transgenic mice" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, April 1997, pages 3058-3063, XP002081315 cited in the application see abstract	1,2
A	JORCYK C.L. ET AL.: "Multiple regulatory regions control the expression of Ets-1 in the developing mouse: vascular expression conferred by intron 1" CELLULAR AND MOLECULAR BIOLOGY, vol. 43, no. 2, March 1997, pages 211-225, XP002081894 cited in the application see abstract	1,2
Α	PATTERSON C. ET AL.: "Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 39, 29 September 1995, pages 23111-23118, XP002081230 cited in the application	
A	QUANDT K. ET AL.: "MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data" NUCLEIC ACIDS RESEARCH, vol. 23, no. 23, 1995, pages 4878-4884, XP002081231 cited in the application	

...iernational application No.

PCT/EP 98/03318

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claims 34, 35 and 39 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
Claims Nos.: because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This International Searching Authority found multiple inventions in this international application, as follows:
As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark on Protest The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

Information on patent family members

In an anal Application No
PCT/EP 98/03318

Patent document cited in search report	Publication date	Patent family member(s)	Publication date	
WO 9717359 A	15-05-1997	AU 7446696 A	29-05-1997	

PCT

WIPO PCT

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

(PCT Article 36 and Rule 70)

Applicant's or	agent's file reference	FOR FURTUED ACTION	See Notification	on of Transmittal of International camination Report (Form PCT/IPEA/416)	
C 1822 PCT		FOR FURTHER ACTION			
International a	application No.	International filing date (day/mont	, , , l	riority date (day/month/year)	
PCT/EP98	/03318	03/06/1998		03/06/1997	
International I C12N15/85	Patent Classification (IPC) or n	ational classification and IPC			
Applicant					
MAX-PLA	NCK-GESELLSCHAFT Z	ZUR FÖRDERUNG et al.			
1. This int and is t	ernational preliminary exar ransmitted to the applicant	mination report has been prepare according to Article 36.	ed by this Intern	ational Preliminary Examining Authority	
2. This RE	EPORT consists of a total of	of 8 sheets, including this cover	sheet.		
be (se	This report is also accompanied by ANNEXES, i.e. sheets of the description, claims and/or drawings which have been amended and are the basis for this report and/or sheets containing rectifications made before this Authority (see Rule 70.16 and Section 607 of the Administrative Instructions under the PCT). These annexes consist of a total of 6 sheets.				
3. This re	port contains indications re	elating to the following items:			
1	Basis of the report				
11	☑ Priority			Lind strict applies bility	
111	Non-establishment of	opinion with regard to novelty, i	nventive step a	nd industrial applicability	
IV.	☐ Lack of unity of inven	tion	4	the stop or industrial applicability:	
V	Reasoned statement citations and explana	under Article 35(2) with regard t tions suporting such statement	o novelty, inver	tive step or industrial applicability;	
VI	☐ Certain documents of	cited			
VII	☐ Certain defects in the	international application			
VIII		on the international application			
	_				
Date of subr	nission of the demand	Date	of completion of t	nis report	
24/11/199	98				
Name and n	nailing address of the internation	onal Author	orized officer	SCO S MATERICA	

Herrmann, K

Telephone No. (+49-89) 2399 2670

European Patent Office

Fax: (+49-89) 2399-4465

Tel. (+49-89) 2399-0 Tx: 523656 epmu d

D-80298 Munich

preliminary examining authority:

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP98/03318

I.	Basi	s of	the	re	port
----	------	------	-----	----	------

1.	This report has been drawn on the basis of (substitute sheets which have been furnished to the receiving Office in response to an invitation under Article 14 are referred to in this report as "originally filed" and are not annexed to the report since they do not contain amendments.):					
	Des	cription, pages:				
	1-72	2	as originally filed			
	Cla	ims, No.:				
	1-40)	as received on	04/06/1999	with letter of	04/06/1999
	Dra	wings, sheets:				
	1/2	1-21/21	as originally filed			
2.	The	amendments have	e resulted in the cancellation	of:		
	П	the description	nages:			
		the description, the claims,	pages: Nos.:			
		the drawings,	sheets:			
3.		This report has be considered to go l	een established as if (some obeyond the disclosure as file	of) the amendmer d (Rule 70.2(c)):	nts had not been r	made, since they have been
4.	Additional observations, if necessary:					
		see separate she	eet			
H.	Pric	ority				
1.		This report has be prescribed time lin	een established as if no prior nit the requested:	ity had been clair	med due to the fai	ilure to fumish within the
		□ copy of the e	arlier application whose prio	rity has been clai	med.	
		☐ translation of	the earlier application whos	e priority has bee	n claimed.	
2.		This report has be	een established as if no prior	ity had been clair	med due to the fa	ct that the priority claim has

INTERNATIONAL PRELIMINARY EXAMINATION REPORT

International application No. PCT/EP98/03318

been found invalid.

Thus for the purposes of this report, the international filing date indicated above is considered to be the relevant date.

3. Additional observations, if necessary:

see separate sheet

III. Non-establishment of opinion with regard to novelty,	, inventive step and industrial applicability
---	---

The questions whether the claimed invention appears to be novel, to involve an inventive step (to be non-obvious), or to be industrially applicable have not been examined in respect of:

	the entire international application.
⊠	claims Nos. 34, 35, 39, 40.
becau	se:
⊠	the said international application, or the said claims Nos. 34, 35, 39, 40 relate to the following subject matter which does not require an international preliminary examination (<i>specify</i>):
	see separate sheet
	the description, claims or drawings (indicate particular elements below) or said claims Nos. are so unclear that no meaningful opinion could be formed (specify):
	the claims, or said claims Nos. are so inadequately supported by the description that no meaningful opinion could be formed.
	no international search report has been established for the said claims Nos

INTERNATIONAL PRELIMINARY **EXAMINATION REPORT**

International application No. PCT/EP98/03318

V. Reasoned statement under Article 35(2) with regard to novelty, inventive step or industrial applicability; citations and explanations supporting such statement

1. Statement

Novelty (N)

Yes:

Claims 19, 23-25, 29-33, 36-38

No:

Claims 1-18, 20-22, 26-28

Inventive step (IS)

Yes:

Claims 19, 23-25, 29-33, 36-38

No:

Claims 1-18, 20-22, 26-28

Industrial applicability (IA)

Yes:

Claims 1-33, 36-38

No:

Claims

2. Citations and explanations

see separate sheet

VIII. Certain observations on the international application

The following observations on the clarity of the claims, description, and drawings or on the question whether the claims are fully supported by the description, are made:

see separate sheet

INTERNATIONAL PRELIMINARY

International application No. PCT/EP98/03318

EXAMINATION REPORT - SEPARATE SHEET

(Basis of the opinion) Re ITEM I

The amended claims 1-40 filed with letter of 04.06.99 can be regarded as meeting the requirements of Art. 34(2)(b) PCT.

(Priority) Re ITEM II

The priority document pertaining to the present application was not available at the time this international preliminary examination report (IPER) was established. Hence, the current assessment is based on the assumption that all claims enjoy priority rights from the filing date of the priority document (03.06.97).

(Non-establishment of opinion) Re ITEM III

As far as the subject-matter of claims 34, 35, 39 and 40 is directed to in vivo methods, it is also directed to methods for treatment of the human or animal body and thus, excluded from examination by Art. 34(4)(a)(i) PCT in combination with Rule 67.1(iv) PCT.

No unified criteria exist among the PCT member states for the assessment whether the treatment of the human or animal body is industrially applicable or not. The patentability can also be dependent upon the formulation of the claims. The EPO, for example, does not recognize as industrially applicable the subjectmatter of claims to the use of a compound in medical treatment, but will allow, however, claims to a known compound for first use in medical treatment and the use of such a compound for the manufacture of a medicament for a new medical treatment.

(Novelty, inventive step, industrial applicability) Re ITEM V

Summary of the present application 1

The present application is related to the Flk-1 gene (fetal liver kinase-1/kinaseinsert domain-containing receptor/VEGF-receptor 2). Flk-1 is a receptor for the endothelial mitogen VEGF (vascular endothelial growth factor). Through

interaction with Flk-1, VEGF plays critical roles in growth and maintenance of vascular endothelial cells and in the development of new blood vessels. More specifically, the application is related to a 510 bp regulatory sequence in intron 1 of the Flk-1 gene (Fig. 12: "Flk-1 intron enhancer"; nucleotides 10094-10608 of SEQ ID NO:1). The application is also related to various uses of said regulatory sequence.

2 Citations

The documents mentioned in this IPER are numbered as in the international search report dated 23.10.98, i.e. D1 corresponds to the first document of the search report etc.

3 Novelty (Art. 33(2) PCT)

- 3.1 The subject-matter of <u>claims 19, 23-25, 29-33 and 36-38</u> has not been made available to the public by any of the available prior art documents and can therefore be regarded as novel.
- 3.2 The subject-matter of claims 1-18, 20-22 and 26-28 does not meet the requirements of Art. 33(2) and 33(3) PCT.
- 3.3 **D3** (Schlaeger, T.M. et al.) discloses an endothelium-specific enhancer in the first intron of the murine *TIE*2 gene (see abstract and Fig. 4 of D3). Since no degree of homology is given in <u>claim 1</u> (cf. description p. 8, l. 9-11), the enhancer of **D3** is regarded as novelty destroying for the subject-matter of <u>claim 1</u>. Genes/proteins can have a common evolutionary origin and still exhibit distinct properties. In the case of Flk-1 and TIE-2 there even is a strong indication for some common evolutionary origin: A significant amino acid sequence similarity can be found in the intracellular tyronsine kinase domain of the Flk-1 gene and the TIE-2 gene. Besides, a particular product's origin cannot be used to establish novelty of the product *per se*.

- 3.4 In view of the novelty-objection raised under **item V, 3.3**, the further embodiments in <u>claims 2-18, 20-22 and 26-28</u> are also not novel over the subject-matter disclosed in **D3** (also cf. **item VIII**).
- 4 Inventive step (Art. 33(3) PCT)

The subject-matter of <u>claims 19, 23-25, 29-33 and 36-38</u> cannot be derived from the available prior art in an obvious manner and therefore complies with the requirements of Art. 33(3) PCT.

5 Industrial applicability (Art. 33(4) PCT)

Claims 1-33 and 36-38 meet the criteria as set forth by Art. 33(4) PCT.

Re ITEM VIII (Certain observations on the international application)

- The present application contains such a high number of independent claims (17 out of 40) that the application as a whole lacks conciseness (Art. 6 EPC). Claims directed to the same category should be made dependent upon each other to meet the requirements of Art. 6 PCT (e.g. claims 29-32, claims 36-38, claims 24 and 25).
- Concerning the claims directed to the regulatory DNA sequence of present application (e.g. <u>claim 1</u>), attention is drawn to Rule 6.3(a) PCT. Said Rule requires that the matter for which protection is sought be defined in terms of technical features of the invention (also cf. PCT Guidelines III-4.4, as in force from 09.10.98). A DNA molecule is a chemical compound which can be clearly and unambiguously defined by its chemical structure, i.e., its nucleic acid sequence.
- The same objection (**item VIII**, **2**) applies to <u>claim 3(f)</u> wherein the expression "a fragment, analogue or derivative capable of conferring expression in endothelial cells in vivo" renders the scope of e.g. <u>claim 3(f)</u> unclear (Art. 6 PCT). It is completely open to interpretation which fragment, analogue or derivative, i.e. which sequences fall under the scope of said claim.

INTERNATIONAL PRELIMINARY International application No. PCT/EP98/03318 EXAMINATION REPORT - SEPARATE SHEET

General references to "hybridization" (e.g. <u>claims 3(d) and 9(c)</u>) without clearly specifying any further requirement of the nucleic acid to be hybridized are ambiguous and thus unclear for the following reasons: (i) The isolated nucleotide can be as short as 5 or 10 nucleotides (the claim does not require that said polynucleotide capable of hybridizing encodes anything. (ii) The word comprising implies the presence of further unrelated sequences. The scope of the claim is not clearly defined as far as the claimed isolated nucleic acids could well hybridize with said unrelated sequence but not with a regulatory or a promoter sequence, respectively (Art. 6 PCT).




(PCT Article 18 and Rules 43 and 44)

Applicant's or agent's file reference		of Transmittal of International Search Report 220) as well as, where applicable, item 5 below.
C 1822 PCT International application No.	International filing date (day/month/year)	(Earliest) Priority Date (day/month/year)
PCT/EP 98/03318	03/06/1998	03/06/1997
Applicant		
MAX-PLANCK-GESELLSCHAFT Z	UR FÖRDERUNG et al.	
This International Search Report has bee according to Article 18. A copy is being tra	n prepared by this International Searching Aut ansmitted to the International Bureau.	hority and is transmitted to the applicant
This International Search Report consists X It is also accompanied by a cop	of a total of <u>5</u> sheets. y of each priorart document cited in this report	:
1. [X] Certain claims were found un	searchable(see Box I).	
2. Unity of invention is lacking(s	ee Box II).	
	ntains disclosure of a nucleotide and/or amin I out on the basis of the sequence listing	o acid sequence listing and the
	d with the international application.	
furn	nished by the applicant separately from the inte	rnational application,
	but not accompanied by a statement to the matter going beyond the disclosure in the	
Trai	nscribed by this Authority	
4. With regard to the title , X the	text is approved as submitted by the applicant	
the	text has been established by this Authority to r	ead as follows:
5. With regard to the abstract,	text is approved as submitted by the applicant	
the Box	text has been established, according to Rule 3 III. The applicant may, within one month from trch Report, submit comments to this Authority	8.2(b), by this Authority as it appears in the date of mailing of this International
6. The figure of the drawings to be publ	ished with the abstract is:	
	suggested by the applicant.	None of the figures.
bec	ause the applicant failed to suggest a figure.	
bec	ause this figure better characterizes the invent	ion.



ernational application No.
PCT/EP 98/03318

Box I	Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)
This Inte	ernational Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:
1. X	Claims Nos.: because they relate to subject matter not required to be searched by this Authority, namely: Remark: Although claims 34, 35 and 39 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition. Claims Nos.:
د. ا	because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out. specifically:
3.	Claims Nos.: because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).
Box II	Observations where unity of invention is lacking (Continuation of item 2 of first sheet)
This Inte	ernational Searching Authority found multiple inventions in this international application, as follows:
1.	As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2.	As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invitepayment of any additional fee.
3.	As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4.	No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:
Remark	The additional search fees were accompanied by the applicant's protest. No protest accompanied the payment of additional search fees.



A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 C12N15/85 C12N15/12 C12N15/19 C07K14/47 C07K14/52
C12N15/58 C12N9/72 C12N15/53 C12N9/02 C12N15/23
C07K14/57 C12N15/16 C07K14/58 C12N5/10 A61K48/00

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 6 C12N C07K A61K C12Q A01K G01N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched


Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOC	いいドム・ラ	CONSIDERED	I TO BE RELEVANT

Category °	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 97 17359 A (REGENTS OF UNIVERSITY OF CALIFORNIA (US); WILLIAMS L.; MORISHITA K.) 15 May 1997	1,4,10, 12,14, 16-18, 20-22, 25,40
	see abstract see page 2, line 32 - page 3, line 7 see page 45, line 4-31 see page 53 - page 59; claims	
	-/	


Further documents are listed in the continuation of box C.	X Patent family members are listed in annex.
Special categories of cited documents: "A" document defining the general state of the art which is not considered to be of particular relevance "E" earlier document but published on or after the international filling date "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means "P" document published prior to the international filling date but later than the priority date claimed	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. "3" document member of the same patent family
Date of the actual completion of theinternational search	Date of mailing of the international search report
23 October 1998	11/11/1998
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk	Authorized officer
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016	Macchia, G

2



		L	
A. CLASSI IPC 6	FICATION OF SUBJECT MATTER C12Q1/68 A01K67/027 G01N33/5	60 A61K35/00	
	o International Patent Classification (IPC) or to both national classifica	ation and IPC	
	SEARCHED cumentation searched (classification system followed by classification	on symbols)	
William GC	realise figures (substitution system followed by substitution		
Documental	tion searched other than minimumdocumentation to the extent that so	uch documents are included in the fields sea	arched
Electronic d	ata base consulted during the international search (name of data bas	se and, where practical, search terms used)	:
C. DOCUM	ENTS CONSIDERED TO BE RELEVANT		
Category °	Citation of document, with indication, where appropriate, of the rele	evant passages	Relevant to claim No.
A	RÖNICKE V ET AL: "Characterizati endothelium-specific murine vascuendothelial growht factor receptor (Flk-1) promoter" CIRCULATION RESEARCH, vol. 79, no. 2, August 1996, page 277-285, XP000604137 cited in the application see page 279, right-hand column, see page 280; figure 2 see page 282; figure 5B see page 283, left-hand column, lef	llar or-2 es line 6-7	1,2
X Furth	ner documents are listed in the continuation of box C.	X Patent family members are listed in	n annex.
° Special ca	tegories of cited documents :	"T" later document published after the inter	
	ent defining the general state of the art which is not	or priority date and not in conflict with cited to understand the principle or the	the application but
"E" earlier o	lered to be of particular relevance document but published on or after the international	invention "X" document of particular relevance; the c	laimed invention
filing d "L" docume	late ent which may throw doubts on priority claim(s) or	cannot be considered novel or cannot involve an inventive step when the do	be considered to
which	tarrational de la calabita la discussión la più additiona de la calabitación	"Y" document of particular relevance; the c cannot be considered to involve an inv	laimed invention
"O" docume	ent referring to an oral disclosure, use, exhibition or means	document is combined with one or mo ments, such combination being obviou	re other such docu-
"P" docume	ent published prior to the international filing date but	in the art. "&" document member of the same patent!	amily
	actual completion of theinternational search	Date of mailing of the international sear	
2	3 October 1998		
Name and r	nailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2	Authorized officer	
	NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo ni,	Macchia C	
	Fax: (+31-70) 340-3016	Macchia, G	

2



		EP 98/03318
C.(Continua	ation) DOCUMENTS CONSIDERED TO BE RELEVANT	
Category °	Citation of document, with indication,where appropriate, of the relevant passages	Relevant to claim No.
А	SCHLAEGER T.M. ET AL.: "Uniform vascular-endothelial-cell -specific gene expression in both embryonic and adult transgenic mice" PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF USA, vol. 94, April 1997, pages 3058-3063, XP002081315 cited in the application see abstract	1,2
А	JORCYK C.L. ET AL.: "Multiple regulatory regions control the expression of Ets-1 in the developing mouse: vascular expression conferred by intron 1" CELLULAR AND MOLECULAR BIOLOGY, vol. 43, no. 2, March 1997, pages 211-225, XP002081894 cited in the application see abstract	1,2
Α	PATTERSON C. ET AL.: "Cloning and functional analysis of the promoter for KDR/flk-1, a receptor for vascular endothelial growth factor" THE JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 270, no. 39, 29 September 1995, pages 23111-23118, XP002081230 cited in the application	
Α	QUANDT K. ET AL.: "MatInd and MatInspector: new fast and versatile tools for detection of consensus matches in nucleotide sequence data" NUCLEIC ACIDS RESEARCH, vol. 23, no. 23, 1995, pages 4878-4884, XP002081231 cited in the application	

on on patent family members



Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9717359 A	15-05-1997	AU 7446696 A	29-05-1997